Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Plandai Biotechnology's enterprise value is $0.45 Mil.
Plandai Biotechnology's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was $-19.77 Mil. Therefore, Plandai Biotechnology's EV-to-EBITDA for today is -0.02.
The historical rank and industry rank for Plandai Biotechnology's EV-to-EBITDA or its related term are showing as below:
PLPL'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -0.02 Med: 0 Max: 0
Current: -0.02
PLPL's EV-to-EBITDA is not ranked
in the Business Services industry.
Industry Median: 7.74
vs PLPL: -0.02
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Plandai Biotechnology's PE Ratio (TTM) for today is calculated as:
Plandai Biotechnology's share price for today is $1.0E-5.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Plandai Biotechnology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.003.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Plandai Biotechnology EV-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Plandai Biotechnology's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Specialty Business Services subindustry, Plandai Biotechnology's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Plandai Biotechnology EV-to-EBITDA vs Business Services Industry
For the Business Services industry and Industrials sector, Plandai Biotechnology's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Plandai Biotechnology's EV-to-EBITDA falls into.
Plandai Biotechnology's current Enterprise Value is $0.45 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Plandai Biotechnology's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was $-19.77 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Plandai Biotechnology (PLPL) has a EV-to-EBITDA of -0.02 as of Aug. 03, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Plandai Biotechnology.
Is Plandai Biotechnology's EV-to-EBITDA too high?
Plandai Biotechnology's current EV-to-EBITDA is -0.02.
How does Plandai Biotechnology's EV-to-EBITDA compare to CRGH and TCRI?
Plandai Biotechnology's EV-to-EBITDA of -0.02 can be compared against companies in the Business Services industry. The industry median EV-to-EBITDA is 7.74. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Business Services company?
The median EV-to-EBITDA among Business Services companies is 7.74, based on 903 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Plandai Biotechnology. For the Business Services industry, the median EV-to-EBITDA is 7.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Plandai Biotechnology's current EV-to-EBITDA is -0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Plandai Biotechnology stock overvalued right now?
Plandai Biotechnology (PLPL) has a current EV-to-EBITDA of -0.02. The current EV-to-EBITDA is -0.02. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Plandai Biotechnology (PLPL), the current EV-to-EBITDA is -0.02 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLPL has been successfully added to your 
